

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 June 2011 (16.06.2011)

(10) International Publication Number
WO 2011/069799 A1

PCT

(51) International Patent Classification:

C07K 16/28 (2006.01) **A61P 35/00** (2006.01)
A61K 39/395 (2006.01) **A61P 5/08** (2006.01)

(21) International Application Number:

PCT/EP2010/067747

(22) International Filing Date:

18 November 2010 (18.11.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

09075546.3 10 December 2009 (10.12.2009) EP

(71) Applicant (for all designated States except US): **BAYER SCHERING PHARMA AG** [DE/DE]; Müllerstrasse 178, 13353 Berlin (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **OTTO, Christiane** [DE/DE]; Müllerstr. 178, 13342 Berlin (DE). **WOLF, Siegmund** [DE/DE]; Müllerstr. 178, 13342 Berlin (DE). **FREIBERG, Christoph** [DE/DE]; Aprather Weg, 42096 Wuppertal (DE). **HARRENGA, Axel** [DE/DE]; Aprather Weg, 42096 Wuppertal (DE). **GREVEN, Simone** [DE/DE]; Aprather Weg, 42096 Wuppertal (DE). **TRAUTWEIN, Mark** [DE/DE]; Aprather Weg, 42096 Wuppertal (DE). **BRUDER, Sandra** [DE/DE]; Aprather Weg, 42096 Wuppertal (DE). **EICKER, Andrea** [DE/DE]; Nattermannallee 1, 50829 Köln (DE). **WILMEN, Andreas** [DE/DE]; Nattermannallee 1, 50829 Köln (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: NEUTRALIZING PROLACTIN RECEPTOR ANTIBODIES AND THEIR THERAPEUTIC USE

(57) Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 005- C04, as well as matured forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.



WO 2011/069799 A1